Tao Synergies Inc. Common Stock and Xilio Therapeutics, Inc. Common Stock
TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.
Open TAOX dashboard ↗Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Open XLO dashboard ↗You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.
Sign in →